Akumentis Healthcare launches synthetic CBD for epilepsy
时间:2024-06-29 04:26:45 阅读(143)
Akumentis Healthcare Limited on Thursday announced that it has launched Clasepi. According to the company’s press statement, Clasepi, DCGI-approved prescription cannabidiol (CBD) is specifically formulated to address seizures linked with Lennox-Gastaut Syndrome (LGS), Dravet Syndrome, or Tuberous Sclerosis Complex (TSC) in patients aged 1 year and older.
Clasepi marks a development as the first synthetic CBD product of its kind to be made available in India, it claimed. The product with THC content below 0.1%, stands out for its non-psychotropic nature.
“Patients grappling with a rare and severe form of epilepsy often endure a protracted journey to obtain an accurate diagnosis, tolerating nearly five years of uncontrolled seizures from the onset. In certain instances, individuals may enter adulthood without a precise diagnosis, despite wrestling with conditions like LGS, DS, or TSC.. We understand the immense physical and emotional toll that frequent seizures can have on patients and their families. This is the driving force behindour commitment to developing novel solutions that effectively relieves the complexities of these disorders,” Kanishk Jain, Executive Director,Akumentis said.
According to the World Health Organisation (WHO), epilepsy constitutes a considerable portion of the global disease burden, affecting approximately 50 million people worldwide, with 20% of patients residing in India.
WHO asserts that up to 70% of individuals with epilepsy could achieve seizure freedom with the proper use of progressive anti seizure medicines. Beyond theseizures themselves, pervasive myths and discrimination surrounding epilepsy create additional hurdles for affected individuals and their families. In India, a sizable number of patients suffers from Lennox-Gastaut Syndrome (LGS), Dravet Syndrome, or Tuberous Sclerosis Complex (TSC) for whom doctors will find clasepi as a new armamentarium in epilepsy therapy protocol.
Clasepi comes with important usage considerations; it is not recommended for individuals allergic to cannabidiol or any of its ingredients. Akumentis stresses the significance of adhering to healthcare providers’ prescription guidance for optimal use and safe consumption, it added.
上一篇:Gold prices rise, LTV ratios shrink
下一篇:Zephyr Peacock plans 7-9 investments from $100-million third fund in next 2 years
猜你喜欢
- 5 ways to support your mental health and manage stress in 2024
- Gold prices slip on stronger dollar and FED rate hike expectations, expect sideways to down move this week
- Gold Price Today, 5 July- Gold rises modestly; traders eye US Labour data, FOMC June meeting minutes
- Gold Price Today, 24 July- Gold to remain range-bound ahead of US Fed meeting; other central banks also eyed
- Adani Ports & Special Economic Zone shares jumps 3 per cent
- 18% GST on fees charged by Sebi
- OPEC+ agrees deep cuts to oil production despite US pressure
- OYO IPO valuation falls in private market after SoftBank’s reported markdown
- Petrol and diesel price August 24- Fuel cost unchanged; Check prices in Delhi, Mumbai, other cities here